NCT06917209

Brief Summary

Dissociative symptoms and disorders are particularly prevalent in the general population and among people suffering from psychiatric disorders. To date, no treatment has proven effective for this type of problem. Exploratory studies (without control group) have been carried out. Among these studies, dissociation-focused cognitive behavioral therapy (DF-CBT) seems promising. DF-CBT is based on a solid empirical model that has received numerous scientific evidence.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
140

participants targeted

Target at P50-P75 for not_applicable

Timeline
13mo left

Started May 2025

Typical duration for not_applicable

Geographic Reach
1 country

8 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress48%
May 2025May 2027

First Submitted

Initial submission to the registry

April 1, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 8, 2025

Completed
1 month until next milestone

Study Start

First participant enrolled

May 16, 2025

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 22, 2026

Expected
9 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 22, 2027

Last Updated

February 10, 2026

Status Verified

February 1, 2026

Enrollment Period

1.3 years

First QC Date

April 1, 2025

Last Update Submit

February 5, 2026

Conditions

Dissociative Disorder

Outcome Measures

Primary Outcomes (1)

  • Difference in Dissociative Experience Scale (DES)

    Difference in Dissociative Experience Scale (DES) between randomization and 3 months after. The DES assesses dissociation through 28 items. The total score ranges between 0 and 100, where high scores indicate high levels of dissociation.

    Between randomization and 3 months after

Secondary Outcomes (6)

  • Hetero-administered visual analogue scale

    At randomization, 3 months and 6 months after

  • Dissociation Questionnaire (DIS-Q)

    At randomisation, 3 months and 6 months after

  • Hospital Anxiety Depression Scale (HADS)

    Randomization, 3 months and 6 months after

  • Post traumatic stress disorder checklist scale (PCL-5)

    Randomization, 3 months and 6 months after

  • Satisfaction With Life Scale (SWLS)

    Randomization, 3 months and 6 months after

  • +1 more secondary outcomes

Study Arms (2)

The experimental group will receive 9 weekly sessions of DF-CBT psychotherapy.

EXPERIMENTAL
Other: CBT-CD psychotherapy

The control group will receive 9 weekly relaxation sessions.

NO INTERVENTION

Interventions

CBT-CD psychotherapyOTHER

9 weekly sessions of CBT-CD psychotherapy

The experimental group will receive 9 weekly sessions of DF-CBT psychotherapy.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ≥ 18 years
  • Membership of a social security scheme
  • Participant's express consent
  • Have at least one diagnosis of dissociative disorder among the following:
  • depersonalization/derealization disorder, dissociative identity disorder, unspecified dissociative disorder.
  • Be able to carry out psychotherapy sessions.
  • If taking psychiatric medication, treatment must have been stable for at least 30 days.

You may not qualify if:

  • Present one of the following current diagnoses: substance use disorder (excluding tobacco), neurodevelopmental disorder, anorexia nervosa, severe depressive disorder, schizophrenia spectrum disorder, bipolar disorder, personality disorder other than borderline personality disorder.
  • Present cognitive deficits.
  • Be engaged in psychotherapeutic work.
  • Be undergoing benzodiazepine treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

Psychiatrie / CHU ANGERS

Angers, France

NOT YET RECRUITING

Centre régional du Psychotraumatisme des Hauts de France / CHU LILLE

Lille, France

NOT YET RECRUITING

Urgences psychiatrique / CHU MONTPELLIER

Montpellier, France

NOT YET RECRUITING

Unité de neuromodulation en psychiatrie / CHU NANTES

Nantes, France

NOT YET RECRUITING

Centre départemental de Psychotraumatologie (unité TCC) / ORLEANS

Orléans, France

NOT YET RECRUITING

Centre Régional du Psychotraumatisme du Grand Est / CHU STRASBOURG

Strasbourg, France

NOT YET RECRUITING

Centre Régional du Psychotraumatisme CRP / CHRU TOURS

Tours, France

RECRUITING

Clinique Psychiatrique Universitaire / CHRU de Tours

Tours, France

RECRUITING

MeSH Terms

Conditions

Dissociative Disorders

Condition Hierarchy (Ancestors)

Mental Disorders

Study Officials

  • Alexis VANCAPPEL, PhD

    Clinique Psychiatrique Universitaire / CHRU de Tours

    STUDY CHAIR

  • Wissam EL HAGE, MD-PhD

    Clinique Psychiatrique Universitaire CPU / CHRU de Tours

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Alexis VANCAPPEL, PhD

CONTACT

02.34.37.89.47alexis.vancappel@univ-tours.fr

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 1, 2025

First Posted

April 8, 2025

Study Start

May 16, 2025

Primary Completion (Estimated)

August 22, 2026

Study Completion (Estimated)

May 22, 2027

Last Updated

February 10, 2026

Record last verified: 2026-02

Locations

FR(8)